A
Arlene O. Siefker-Radtke
Researcher at University of Texas MD Anderson Cancer Center
Publications - 222
Citations - 12998
Arlene O. Siefker-Radtke is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Bladder cancer & Cancer. The author has an hindex of 50, co-authored 199 publications receiving 10150 citations. Previous affiliations of Arlene O. Siefker-Radtke include University of Texas Health Science Center at Houston & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
Woonyoung Choi,Sima P. Porten,Seungchan Kim,Daniel L. Willis,Elizabeth R. Plimack,Jean H. Hoffman-Censits,Beat Roth,Tiewei Cheng,Mai Tran,Mai Tran,I-Ling Lee,Jonathan Melquist,Jolanta Bondaruk,Tadeusz Majewski,Shizhen Zhang,Shanna Pretzsch,Keith A. Baggerly,Arlene O. Siefker-Radtke,Bogdan Czerniak,Colin P.N. Dinney,David J. McConkey,David J. McConkey +21 more
TL;DR: P53-like MIBCs were consistently resistant to neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy, and all chemoresistant tumors adopted a p53- like phenotype after therapy.
Journal ArticleDOI
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma,Margitta Retz,Arlene O. Siefker-Radtke,Ari David Baron,Andrea Necchi,Jens Bedke,Elizabeth R. Plimack,Daniel A. Vaena,Marc-Oliver Grimm,Sergio Bracarda,Jose Angel Arranz,Sumanta K. Pal,Chikara Ohyama,Abdel Saci,Xiaotao Qu,Alexandre Lambert,Suba Krishnan,Alex Azrilevich,Matthew D. Galsky +18 more
TL;DR: Nivolumab monotherapy provided meaningful clinical benefit, irrespective of PD-L1 expression, and was associated with an acceptable safety profile in previously treated patients with metastatic or surgically unresectable urothelial carcinoma.
Journal ArticleDOI
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Yohann Loriot,Andrea Necchi,Se Hoon Park,Jesús García-Donas,Robert Huddart,Elizabeth A. Burgess,Mark D. Fleming,A. Rezazadeh,Begoña Mellado,Sergei Varlamov,Monika Joshi,Ignacio Duran,Scott T. Tagawa,Yousef Zakharia,B. Zhong,K. Stuyckens,A. Santiago-Walker,P. De Porre,A. O'Hagan,A. Avadhani,Arlene O. Siefker-Radtke +20 more
TL;DR: The use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations.
Journal ArticleDOI
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
Aurélie Kamoun,Aurélien de Reyniès,Yves Allory,Yves Allory,Gottfrid Sjödahl,A. Gordon Robertson,Roland Seiler,Katherine A. Hoadley,Clarice S. Groeneveld,Clarice S. Groeneveld,Hikmat Al-Ahmadie,Woonyoung Choi,Mauro A. A. Castro,Jacqueline Fontugne,Jacqueline Fontugne,Pontus Eriksson,Qianxing Mo,Jordan Kardos,Alexandre R. Zlotta,Arndt Hartmann,Colin Dinney,Joaquim Bellmunt,Thomas Powles,Núria Malats,Keith S. Chan,William Y. Kim,David J. McConkey,Peter C. Black,Lars Dyrskjøt,Mattias Höglund,Seth P. Lerner,Francisco X. Real,François Radvanyi,Mattias Aine,Isabelle Bernard-Pierrot,Bogdan Czerniak,Ewan A. Gibb,Jaegil Kim,David J. Kwiatkowski,Thierry Lebret,Fredrik Liedberg,Arlene O. Siefker-Radtke,Nanor Sirab,Ann Taber,John N. Weinstein +44 more
TL;DR: In this paper, a consensus set of six molecular classes (luminal papillary (24%), luminal nonspecified (8), luminal unstable (15), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%) was identified.
Journal ArticleDOI
miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy
Liana Adam,Meng Zhong,Woonyoung Choi,Wei Qi,Milena S. Nicoloso,Ameeta Arora,George A. Calin,Hua Wang,Arlene O. Siefker-Radtke,David J. McConkey,Menashe Bar-Eli,Colin P.N. Dinney +11 more
TL;DR: Members of the miR-200 family appear to control the EMT process and sensitivity to EGFR therapy in bladder cancer cells and the expression of miR -200 is sufficient to restore EGFR dependency at least in some of the mesenchymal bladder cancers cells.